Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA Access the “What This Means” segment CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a discussing the Company’s recent successful Pre-IND meeting with the U.S. Food and Drug Administration and its continued advancement toward a first-in-human trial for ovarian cancer...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Salesforce, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 26 January 2026 in which we reassessed the appropriateness of the ratings in the context o...
Gran Tierra Energy Inc. Provides Operations Update and Certain Preliminary Unaudited 2025 Financial Data Achieved December 2025 Average of 48,235 BOEPD The Highest Monthly Average in Company HistoryDuring the Fourth Quarter 2025 Reached a Daily Production Rate of 10,000 BOPD in Ecuador Multiple Field Development Plans Approved and Fulfilled All Exploration Commitments in EcuadorPreliminary Unaudited 2025 Financial Data CALGARY, Alberta, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) today provided an operat...
Gran Tierra Energy Inc. Announces Exchange Offer of Certain Existing Notes for New Notes and the Solicitation of Consents to Proposed Amendments to the Existing Indenture CALGARY, Alberta, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) today announced the commencement of an offer to Eligible Holders (as defined herein) to exchange (such offer, the “Exchange Offer”) any and all of the Company’s outstanding 9.500% Senior Notes due 2029 (CUSIP: 38500T AC5 / U37016 AC3; ISIN: US38500TAC53 / USU37016AC37) (the “E...
Gran Tierra Energy Inc. Reports Seventh Consecutive Year of South American Reserves Growth Seventh Consecutive Year of South American Reserves Growth With Over 100% Reserve Replacement PDP and 2PWorld Class Resource Base Captured Including 2P Reserves of 258 MMBOE1P and 2P Reserve Life Index of 8 and 15 Years, RespectivelyNet Present Value Before Tax Discounted at 10% of $1.5 Billion (1P), $2.5 Billion (2P), and $3.3 Billion (3P)Net Asset Value per Share of $22.63 Before Tax and $13.62 After Tax (1P), and $51.09 Before Tax and $31.19 After Tax (2P) Unrisked 2C Resources of 74 MMBOE (Glaucon...
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program (JEAP), a highly competitive initiative launched by the Japan External Trade Organization (JETRO). JEAP drew approximately 70 regenerative medicine companies f...
Warner Bros. Discovery, Inc. (WBD - $28.24) and Netflix Inc. (NFLX - $85.70)News Reports Senate Antitrust Panel Chair Raises Concerns Over Pending Merger. According to the WSJ, Senator Mike Lee, chairman of the Senate Judiciary Committee's Subcommittee on Antitrust, Competition Policy & Consume
A director at Salesforce Inc sold 3,893 shares at 238.704USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readiness Company on track to initiate first-in-human (FIH) trial for the treatment of ovarian cancer in the second half of 2026 CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the successful completion of its r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.